000513 丽珠集团
已收盘 11-16 15:00:00
资讯
新帖
简况
股市必读:丽珠集团新发布《广东崇立律师事务所关于丽珠医药集团股份有限公司2026年第二次临时股东会的法律意见书》
证券之星 · 11-16 05:01
股市必读:丽珠集团新发布《广东崇立律师事务所关于丽珠医药集团股份有限公司2026年第二次临时股东会的法律意见书》
丽珠集团(000513)披露2026年第二次临时股东会决议公告,11月13日股价上涨0.44%
证券之星 · 11-13
丽珠集团(000513)披露2026年第二次临时股东会决议公告,11月13日股价上涨0.44%
丽珠集团(000513)11月6日主力资金净买入1449.32万元
证券之星 · 11-09
丽珠集团(000513)11月6日主力资金净买入1449.32万元
股市必读:丽珠集团新发布《关于为子公司提供担保的进展公告》
证券之星 · 11-06
股市必读:丽珠集团新发布《关于为子公司提供担保的进展公告》
丽珠集团(000513)披露为子公司提供担保的进展公告,11月04日股价上涨2.14%
证券之星 · 11-04
丽珠集团(000513)披露为子公司提供担保的进展公告,11月04日股价上涨2.14%
股市必读:丽珠集团新发布《H股公告:证券变动月报表》
证券之星 · 11-04
股市必读:丽珠集团新发布《H股公告:证券变动月报表》
丽珠集团(000513)披露证券变动月报表,11月02日股价上涨3.16%
证券之星 · 11-02
丽珠集团(000513)披露证券变动月报表,11月02日股价上涨3.16%
丽珠集团(000513)10月30日主力资金净买入2915.91万元
证券之星 · 11-02
丽珠集团(000513)10月30日主力资金净买入2915.91万元
外企背景总裁不到一年“闪辞”,知名药企90后“药二代”全面接掌!
红星资本局 · 10-28
外企背景总裁不到一年“闪辞”,知名药企90后“药二代”全面接掌!
10月26日丽珠集团涨5.30%,疫苗ETF鹏华基金重仓该股
证券之星 · 10-26
10月26日丽珠集团涨5.30%,疫苗ETF鹏华基金重仓该股
丽珠集团涨5.30%,东海证券一个月前给出“买入”评级
证券之星 · 10-26
丽珠集团涨5.30%,东海证券一个月前给出“买入”评级
股市必读:丽珠集团三季报 - 第三季度单季净利润同比下降24.76%
证券之星 · 10-26
股市必读:丽珠集团三季报 - 第三季度单季净利润同比下降24.76%
丽珠集团(000513)披露2026年三季度报告,10月23日股价上涨3.65%
证券之星 · 10-23
丽珠集团(000513)披露2026年三季度报告,10月23日股价上涨3.65%
丽珠集团前三季度营收73.2亿元 AIDD持续赋能药物研发
同花顺 · 10-23
丽珠集团前三季度营收73.2亿元 AIDD持续赋能药物研发
丽珠集团(000513)9月30日股东户数6.26万户,较上期增加5.15%
证券之星 · 10-23
丽珠集团(000513)9月30日股东户数6.26万户,较上期增加5.15%
丽珠集团:第三季度净利润同比下降24.76%
南方财经网 · 10-23
丽珠集团:第三季度净利润同比下降24.76%
丽珠集团(000513)10月15日主力资金净买入701.36万元
证券之星 · 10-16
丽珠集团(000513)10月15日主力资金净买入701.36万元
【机构调研记录】华宝基金调研丽珠集团、源杰科技
证券之星 · 10-15
【机构调研记录】华宝基金调研丽珠集团、源杰科技
丽珠集团:未来几年制剂国际化的收入增长主要来自产品完成海外注册后形成的销售收入等
南方财经网 · 10-14
丽珠集团:未来几年制剂国际化的收入增长主要来自产品完成海外注册后形成的销售收入等
丽珠集团:莱康奇塔单抗未来将在国内依托公司特药销售团队自主开展商业化
南方财经网 · 10-14
丽珠集团:莱康奇塔单抗未来将在国内依托公司特药销售团队自主开展商业化
加载更多
公司概况
公司名称:
丽珠医药集团股份有限公司
所属行业:
医药制造业
上市日期:
1993-10-28
主营业务:
丽珠医药集团股份有限公司的主营业务是医药产品的研发、生产及销售。公司的主要产品是化学制剂产品、原料药和中间体、中药制剂、生物制品、诊断试剂及设备。公司国内领先的产业体系完备、研产销一体化程度高的大型综合型医药企业集团,长期荣登“中国化学制药行业工业企业综合实力百强”“中国化药企业百强”等权威榜单,先后获评国家高新技术企业、国家技术创新示范企业及国家企业技术中心。
发行价格:
6.38
{"stockData":{"symbol":"000513","market":"SZ","secType":"STK","nameCN":"丽珠集团","latestPrice":31.98,"timestamp":1794812586000,"preClose":31.67,"halted":0,"volume":6873256,"delay":0,"changeRate":0.0098,"floatShares":568000000,"shares":888000000,"eps":1.7539,"marketStatus":"已收盘","change":0.31,"latestTime":"11-16 15:00:00","open":31.58,"high":32.18,"low":31.42,"amount":219000000,"amplitude":0.024,"askPrice":31.98,"askSize":55,"bidPrice":31.97,"bidSize":4,"shortable":0,"etf":0,"ttmEps":1.7539,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794879000000},"marketStatusCode":5,"adr":0,"adjPreClose":31.67,"symbolType":"stock","openAndCloseTimeList":[[1794792600000,1794799800000],[1794805200000,1794812400000]],"highLimit":34.84,"lowLimit":28.5,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":887907171,"isCdr":false,"pbRate":2.16,"roa":"--","peRate":18.233651,"roe":"9.22%","epsLYR":2.27,"committee":-0.575,"marketValue":28395000000,"turnoverRate":0.0121,"status":0,"hkstockBrief":{"symbol":"01513","market":"HK","secType":"STK","nameCN":"丽珠医药","latestPrice":24.98,"timestamp":1794816493003,"preClose":25,"halted":0,"volume":1231740,"delay":0,"premium":"-33.65"},"floatMarketCap":18154000000},"requestUrl":"/m/hq/s/000513","defaultTab":"news","newsList":[{"id":"2683113650","title":"股市必读:丽珠集团新发布《广东崇立律师事务所关于丽珠医药集团股份有限公司2026年第二次临时股东会的法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2683113650","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683113650?lang=zh_cn&edition=full","pubTime":"2026-11-16 05:01","pubTimestamp":1794776475,"startTime":"0","endTime":"0","summary":"公司公告汇总广东崇立律师事务所关于丽珠医药集团股份有限公司2026年第二次临时股东会的法律意见书广东崇立律师事务所确认丽珠医药集团股份有限公司2026年第二次临时股东会的召集和召开程序、召集人资格、出席会议人员资格、表决程序及表决结果均符合相关法律法规及公司章程规定,会议决议合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111600001590.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0187","BK0028","01513","000513","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683195579","title":"丽珠集团(000513)披露2026年第二次临时股东会决议公告,11月13日股价上涨0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2683195579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683195579?lang=zh_cn&edition=full","pubTime":"2026-11-13 17:57","pubTimestamp":1794563877,"startTime":"0","endTime":"0","summary":"截至2026年11月13日收盘,丽珠集团报收于31.67元,较前一交易日上涨0.44%,最新总市值为281.2亿元。该股当日开盘31.52元,最高32.0元,最低31.2元,成交额达2.32亿元,换手率为1.29%。丽珠医药集团股份有限公司于2026年11月12日召开2026年第二次临时股东会,会议由董事会召集,董事长刘大平主持,采用现场与网络投票相结合方式召开。出席股东所持表决权股份总数占公司有表决权股份总数的48.7764%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300032626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000513","BK0187","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682319827","title":"丽珠集团(000513)11月6日主力资金净买入1449.32万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682319827","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682319827?lang=zh_cn&edition=full","pubTime":"2026-11-09 09:29","pubTimestamp":1794187754,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月6日收盘,丽珠集团报收于31.35元,上涨1.72%,换手率2.12%,成交量12.04万手,成交额3.76亿元。近5日资金流向一览见下表:丽珠集团融资融券信息显示,融资方面,当日融资买入1335.03万元,融资偿还2572.89万元,融资净偿还1237.86万元。丽珠集团主营业务:以医药产品的研发、生产及销售为主业,产品涵盖制剂产品、原料药和中间体及诊断试剂及设备,覆盖了消化道、辅助生殖、精神及肿瘤免疫等众多治疗领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110900002124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","000513","BK0187","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681003351","title":"股市必读:丽珠集团新发布《关于为子公司提供担保的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2681003351","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681003351?lang=zh_cn&edition=full","pubTime":"2026-11-06 01:02","pubTimestamp":1793898138,"startTime":"0","endTime":"0","summary":"公司公告汇总:公司于2026年10月为子公司丽珠制药厂和丽珠合成新增担保合计49,000.00万元,截至10月31日实际对外担保余额210,894.83万元,占最近一期经审计归母净资产的15.19%。公司公告汇总关于为子公司提供担保的进展公告丽珠医药集团股份有限公司于2026年10月为子公司丽珠制药厂和珠海保税区丽珠合成制药有限公司分别与中国建设银行、招商银行签署担保协议,合计新增担保金额49,000.00万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600001612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0187","BK0188","BK0239","000513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680057759","title":"丽珠集团(000513)披露为子公司提供担保的进展公告,11月04日股价上涨2.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680057759","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680057759?lang=zh_cn&edition=full","pubTime":"2026-11-04 22:16","pubTimestamp":1793801791,"startTime":"0","endTime":"0","summary":"截至2026年11月4日收盘,丽珠集团报收于30.6元,较前一交易日上涨2.14%,最新总市值为271.7亿元。近日,丽珠医药集团股份有限公司披露《关于为子公司提供担保的进展公告》。其中为丽珠制药厂提供两笔各20,000.00万元的最高额保证担保,为丽珠合成提供9,000.00万元担保,均为主债权最高额连带责任保证。截至2026年10月31日,公司实际对外担保余额为210,894.83万元,占最近一期经审计归母净资产的15.19%,均为对子公司的担保,无逾期及对外担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400043652.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0187","000513","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680677662","title":"股市必读:丽珠集团新发布《H股公告:证券变动月报表》","url":"https://stock-news.laohu8.com/highlight/detail?id=2680677662","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680677662?lang=zh_cn&edition=full","pubTime":"2026-11-04 01:47","pubTimestamp":1793728069,"startTime":"0","endTime":"0","summary":"截至2026年11月3日收盘,丽珠集团报收于29.96元,上涨1.84%,换手率2.34%,成交量13.25万手,成交额3.96亿元。公司公告汇总:丽珠集团提交截至2026年10月31日的H股证券变动月报表,H股数目为299,807,117股,A股数目为588,100,054股,总注册资本为人民币887,907,171元,本月无股份期权、可换股票据或其他股份发行安排。公司公告汇总H股公告:证券变动月报表丽珠医药集团股份有限公司提交截至2026年10月31日的证券变动月报表。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400003247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","161027","BK0187","BK0188","BK0239","000513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680763944","title":"丽珠集团(000513)披露证券变动月报表,11月02日股价上涨3.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680763944","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680763944?lang=zh_cn&edition=full","pubTime":"2026-11-02 22:08","pubTimestamp":1793628526,"startTime":"0","endTime":"0","summary":"截至2026年11月2日收盘,丽珠集团报收于29.42元,较前一交易日上涨3.16%,最新总市值为261.22亿元。该股当日开盘28.5元,最高29.6元,最低28.4元,成交额达4.77亿元,换手率为2.89%。近日,丽珠医药集团股份有限公司披露《证券变动月报表》,提交截至2026年10月31日的股份变动情况。公告显示,公司H股和A股的法定/注册股本均无变动,H股数目为299,807,117股,A股数目为588,100,054股,总注册股本为人民币887,907,171元。本月无股份期权、可换股票据或其他股份发行安排。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200036509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","BK0239","BK0028","000513","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680786112","title":"丽珠集团(000513)10月30日主力资金净买入2915.91万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680786112","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680786112?lang=zh_cn&edition=full","pubTime":"2026-11-02 09:05","pubTimestamp":1793581522,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月30日收盘,丽珠集团报收于28.52元,上涨3.18%,换手率3.09%,成交量17.52万手,成交额4.94亿元。近5日资金流向一览见下表:丽珠集团融资融券信息显示,融资方面,当日融资买入5853.07万元,融资偿还4903.1万元,融资净买入949.97万元。丽珠集团主营业务:以医药产品的研发、生产及销售为主业,产品涵盖制剂产品、原料药和中间体及诊断试剂及设备,覆盖了消化道、辅助生殖、精神及肿瘤免疫等众多治疗领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200003235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0239","BK0028","000513","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678457686","title":"外企背景总裁不到一年“闪辞”,知名药企90后“药二代”全面接掌!","url":"https://stock-news.laohu8.com/highlight/detail?id=2678457686","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678457686?lang=zh_cn&edition=full","pubTime":"2026-10-28 17:13","pubTimestamp":1793178780,"startTime":"0","endTime":"0","summary":"辞职后,王锐不再担任公司任何职务,其所负责工作已完成交接。红星资本局注意到,王锐是一位有着外企背景的医药经理人,于2025年12月31日被振东制药聘任为总裁,至今任职未满一年。王锐原定任期至第六届董事会届满之日即2027年9月10日止。业绩方面,自2022年以来,振东制药的营收持续下滑,归母净利润一直为负。2025年,该公司中药、化药、其他业务收入均同比下滑,仅非药品收入同比增长17.60%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-10-28/doc-iniwuqvv9440864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000513","300363","BK0186","BK0188","BK0028","BK0060","300158","BK0187","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678163602","title":"10月26日丽珠集团涨5.30%,疫苗ETF鹏华基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678163602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678163602?lang=zh_cn&edition=full","pubTime":"2026-10-26 16:39","pubTimestamp":1793003952,"startTime":"0","endTime":"0","summary":"证券之星消息,10月26日丽珠集团涨5.30%,收盘报28.4元,换手率3.51%,成交量19.95万手,成交额5.64亿元。根据2026基金Q3季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为鹏华基金的疫苗ETF鹏华。疫苗ETF鹏华目前规模为0.95亿元,最新净值0.5725,较上一交易日上涨2.49%,近一年下跌18.7%。疫苗ETF鹏华的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600022008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0187","159643","000513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678163133","title":"丽珠集团涨5.30%,东海证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2678163133","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678163133?lang=zh_cn&edition=full","pubTime":"2026-10-26 16:39","pubTimestamp":1793003943,"startTime":"0","endTime":"0","summary":"今日丽珠集团涨5.30%,收盘报28.4元。2026年9月18日,东海证券研究员杜永宏发布了对丽珠集团的研报《公司简评报告:业绩短期承压,新品放量可期》,该研报对丽珠集团给出“买入”评级。公司成熟品种有望逐渐企稳,新产品放量可期,维持“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为中金公司的宋歌。丽珠集团个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600022000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","000513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678136551","title":"股市必读:丽珠集团三季报 - 第三季度单季净利润同比下降24.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678136551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678136551?lang=zh_cn&edition=full","pubTime":"2026-10-26 02:07","pubTimestamp":1792951629,"startTime":"0","endTime":"0","summary":"业绩披露要点:2026年前三季度归母净利润12.88亿元,同比下降26.57%。公司公告汇总2026年三季度报告2026年第三季度营业收入23.20亿元,同比下降18.44%;归属于上市公司股东的净利润3.56亿元,同比下降24.76%。基本每股收益1.45元,同比下降26.02%。经营活动产生的现金流量净额24.92亿元,同比下降1.33%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600000602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677736349","title":"丽珠集团(000513)披露2026年三季度报告,10月23日股价上涨3.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677736349","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677736349?lang=zh_cn&edition=full","pubTime":"2026-10-23 22:38","pubTimestamp":1792766304,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘,丽珠集团报收于26.97元,较前一交易日上涨3.65%,最新总市值为239.47亿元。近日,丽珠集团披露《2026年三季度报告》。公告显示,2026年第三季度营业收入2,319,638,386.27元,同比下降18.44%;归属于上市公司股东的净利润355,906,126.82元,同比下降24.76%。年初至报告期末营业收入7,319,308,094.92元,同比下降19.71%;归属于上市公司股东的净利润1,288,105,339.88元,同比下降26.57%。经营活动产生的现金流量净额2,491,927,678.82元,同比下降1.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300045793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0239","BK0188","BK0028","000513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677226229","title":"丽珠集团前三季度营收73.2亿元 AIDD持续赋能药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2677226229","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677226229?lang=zh_cn&edition=full","pubTime":"2026-10-23 20:32","pubTimestamp":1792758720,"startTime":"0","endTime":"0","summary":" 本报讯(记者张敏)10月23日晚间,丽珠医药集团股份有限公司(以下简称“丽珠集团”)发布的2026年三季度报告显示,前三季度,公司实现营业收入73.2亿元,实现归属于上 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261023/c681041844.shtml","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261023/c681041844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["000513","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677928586","title":"丽珠集团(000513)9月30日股东户数6.26万户,较上期增加5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677928586","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677928586?lang=zh_cn&edition=full","pubTime":"2026-10-23 17:56","pubTimestamp":1792749364,"startTime":"0","endTime":"0","summary":"证券之星消息,近日丽珠集团披露,截至2026年9月30日公司股东户数为6.26万户,较6月30日增加3069.0户,增幅为5.15%。在化学制药行业个股中,丽珠集团股东户数高于行业平均水平,截至9月30日,化学制药行业平均股东户数为3.67万户。从股价来看,2026年6月30日至2026年9月30日,丽珠集团区间涨幅为13.88%,在此期间股东户数增加3069.0户,增幅为5.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300032571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000513","BK0187","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677941266","title":"丽珠集团:第三季度净利润同比下降24.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677941266","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677941266?lang=zh_cn&edition=full","pubTime":"2026-10-23 16:18","pubTimestamp":1792743480,"startTime":"0","endTime":"0","summary":"南财智讯10月23日电,丽珠集团发布三季度报告,第三季度公司实现营业收入23.20亿元,同比下降18.44%;归属于上市公司股东的净利润3.56亿元,同比下降24.76%。前三季度公司实现营业收入73.19亿元,同比下降19.71%;前三季度归属于上市公司股东的净利润12.88亿元,同比下降26.57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610233906282941.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610233906282941.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["000513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675512825","title":"丽珠集团(000513)10月15日主力资金净买入701.36万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675512825","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675512825?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:07","pubTimestamp":1792112828,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月15日收盘,丽珠集团报收于28.03元,上涨0.07%,换手率2.15%,成交量12.23万手,成交额3.46亿元。近5日资金流向一览见下表:丽珠集团融资融券信息显示,融资方面,当日融资买入2377.46万元,融资偿还3860.29万元,融资净偿还1482.83万元。丽珠集团主营业务:以医药产品的研发、生产及销售为主业,产品涵盖制剂产品、原料药和中间体及诊断试剂及设备,覆盖了消化道、辅助生殖、精神及肿瘤免疫等众多治疗领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600008734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","000513","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675000373","title":"【机构调研记录】华宝基金调研丽珠集团、源杰科技","url":"https://stock-news.laohu8.com/highlight/detail?id=2675000373","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675000373?lang=zh_cn&edition=full","pubTime":"2026-10-15 08:11","pubTimestamp":1792023106,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及10月14日披露的机构调研信息,华宝基金近期对2家上市公司进行了调研,相关名单如下:1)丽珠集团 调研纪要:2026年公司经营阶段性承压,主要受成熟产品医保谈判及集采降价影响,预计全年收入降幅与上半年基本持平,利润降幅收窄。2)源杰科技 调研纪要:公司第三季度利润增长主要驱动力来自产能释放,在旺盛市场需求下,业绩实现环比增长,预计2026年第四季度及2027年将继续保持增长态势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500006674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688498","SGXZ81163826.USD","BK0239","BK0187","SGXZ49509284.SGD","BK0214","000513","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675994323","title":"丽珠集团:未来几年制剂国际化的收入增长主要来自产品完成海外注册后形成的销售收入等","url":"https://stock-news.laohu8.com/highlight/detail?id=2675994323","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675994323?lang=zh_cn&edition=full","pubTime":"2026-10-14 09:18","pubTimestamp":1791940739,"startTime":"0","endTime":"0","summary":"南财智讯10月14日电,丽珠集团在投资者关系活动中表示,公司制剂国际化并非简单地将产品一次性授权给当地合作方,而是希望逐步提升重点区域的本地化运营能力。在主要区域,公司会选择重点国家,通过自建团队、收购当地企业或整合本地生产及渠道平台建立区域支点,并在此基础上与当地合作伙伴共同推进周边国家的产品注册、授权和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610143895006736.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610143895006736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK0239","000513","BK0028","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675399451","title":"丽珠集团:莱康奇塔单抗未来将在国内依托公司特药销售团队自主开展商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2675399451","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675399451?lang=zh_cn&edition=full","pubTime":"2026-10-14 09:18","pubTimestamp":1791940680,"startTime":"0","endTime":"0","summary":"南财智讯10月14日电,丽珠集团在投资者关系活动中表示,莱康奇塔单抗是公司未来数年的重点产品之一。公司自2025年起已启动该产品的商业化准备工作,未来将在国内依托公司特药销售团队自主开展商业化。商业化方面,公司计划通过核心专家及临床证据驱动的学术推广,覆盖现有治疗不足、产生耐药或需要更高皮损清除率的患者,同时关注基层市场生物制剂渗透率提升的机会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610143895009524.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610143895009524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","BK0188","000513","BK0239","BK0187"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794851872411,"stockEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":0.1442},{"period":"3month","weight":0.1147},{"period":"6month","weight":0.1121},{"period":"1year","weight":-0.0775},{"period":"ytd","weight":0.0065}],"compareEarnings":[{"period":"1week","weight":-0.0159},{"period":"1month","weight":-0.0306},{"period":"3month","weight":-0.0972},{"period":"6month","weight":-0.1345},{"period":"1year","weight":-0.0972},{"period":"ytd","weight":-0.0923}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"丽珠医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"62609人(较上一季度增加5.15%)","perCapita":"9066股","listingDate":"1993-10-28","address":"广东省珠海市金湾区创业北路38号总部大楼","registeredCapital":"88790万元","survey":" 丽珠医药集团股份有限公司的主营业务是医药产品的研发、生产及销售。公司的主要产品是化学制剂产品、原料药和中间体、中药制剂、生物制品、诊断试剂及设备。公司国内领先的产业体系完备、研产销一体化程度高的大型综合型医药企业集团,长期荣登“中国化学制药行业工业企业综合实力百强”“中国化药企业百强”等权威榜单,先后获评国家高新技术企业、国家技术创新示范企业及国家企业技术中心。","listedPrice":6.38},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丽珠集团,000513,丽珠集团股票,丽珠集团股票老虎,丽珠集团股票老虎国际,丽珠集团行情,丽珠集团股票行情,丽珠集团股价,丽珠集团股市,丽珠集团股票价格,丽珠集团股票交易,丽珠集团股票购买,丽珠集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}